ProteoTech Inc.

ProteoTech Inc., is a private drug development Company founded in 1996 that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloidosis.

With over 180 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1^® for the treatment of mild-to-moderate Alzheimer's disease.

The Company is in late stage pre-clinical development with Synuclere^™ for the treatment of Parkinson's disease, and Systebryl^™ for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere^™ as a nasal spray for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes.


Synuclere™ - ProteoTech's Parkinson's Drug
2009 International Alzheimer's/Parkinson's Conference Presentation - Prague, Czech Republic Download Poster (PDF)

ProteoTech's Alzheimers Target:Beta-amyloid Protein	ProteoTech's Parkinson's Target:Alpha-synuclein

Human Alzheimer's brain filled with amyloid plaques (arrows) (click image to enlarge)	Neuron in the substantia nigra with a Lewy body containing alpha-synuclein (click image to enlarge)
ProteoTech's Type 2 Diabetes Target:Islet Amyloid Polypeptide	ProteoTech's AA Amyloidosis Target:AA Amyloid Protein

Congo red staining of IAPP amyloid deposits in Islet of Langerhans (pancreas) of patient with Type 2 Diabetes (click image to enlarge)	AA Amyloid deposits in liver (click image to enlarge)

News

April, 2009 ProteoTech presents at the 11th annual C21 BioVentures Conference in Napa, California

April, 2009 ProteoTech meets all scientific milestones for the Michael J. Fox foundation LEAPS award to continue development of Synuclere^™ for treatment of Parkinson's disease.

March 09, 2009 ProteoTech presents at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009

February 26, 2009 ProteoTech receives funding from The Michael J. Fox Foundation for Parkinson's Disease research to develop tools for imaging Alpha-Synuclein aggregation in living Parkinson's Brain

December, 2008 ProteoTech's Alzheimer's Drug Exebryl-1^® was featured in the Dec 2008 Issue of Reader's Digest

November 11, 2008 ProteoTech presents at Rodman & Renshaw's 10th Annual Healthcare Conference

August 07, 2008 ProteoTech's Exebryl-1^® enters human clinical trials for the treatment of Alzheimer's Disease

July 29, 2008 Exebryl-1^® Phase I human clinical trial for Alzheimer's disease commences

July 25, 2008 ProteoTech presents at International Alzheimer's Conference—Chicago, IL.

May 28, 2008 ProteoTech receives clearance from FDA to proceed with Phase I human clinical trials for Exebryl-1^®

May 15, 2008 ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

April 28, 2008 ProteoTech files IND for Exebryl-1^® for the treatment of mild-to-moderate Alzheimer's Disease

scroll